• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

凝血酶生成试验在体外评估抗凝逆转方面优于传统检测方法。

Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.

作者信息

Gatt Alex, van Veen Joost J, Woolley Anita M, Kitchen Steve, Cooper Peter, Makris Michael

机构信息

Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK.

出版信息

Thromb Haemost. 2008 Aug;100(2):350-5.

PMID:18690358
Abstract

Even though new anticoagulants are being devised with the notion that they do not require regular monitoring, when bleeding occurs, it is important to have an antidote and a reliable test to confirm whether the anticoagulant effects are persisting. We examined the effects of five heparinoids, unfractionated heparin (UFH), tinzaparin, enoxaparin, danaparoid and fondaparinux on the traditional APTT and anti-Xa assays as well as on the calibrated automated thrombogram (CAT). We also studied the ability of protamine sulphate (PS), NovoSeven, FEIBA and FFP to reverse maximum anticoagulation induced by the different heparinoids. The CAT was the only test to detect the coagulopathy of all the anticoagulants. PS produced complete reversal of UFH, and this could be monitored with all three tests. Tinzaparin can also be completely neutralised in vitro with high doses of PS, but the maximum enoxaparin reversal achieved with PS is only approximately 60%. Fondaparinux does not significantly affect the APTT and PS has no significant effect on its reversal. Only NovoSeven was able to correct the fondaparinux induced CAT abnormalities whilst having no effect on the anti-Xa level. None of the reversal agents was very effective in danaparoid spiked plasma but NovoSeven, at high dose, increased the ETP by 40% and reduced the anti-Xa level from 0.93 to 0.78 IU/ml. We conclude that the CAT is superior to the traditional coagulation tests in that it not only detects the coagulopathy of all the heparinoids but can be also be used to monitor their reversal.

摘要

尽管新型抗凝剂的设计理念是无需定期监测,但出血发生时,拥有解毒剂和可靠的检测方法以确认抗凝效果是否持续存在非常重要。我们研究了五种类肝素(普通肝素(UFH)、替扎肝素、依诺肝素、达那肝素和磺达肝癸钠)对传统活化部分凝血活酶时间(APTT)和抗Xa检测以及校准自动血栓图(CAT)的影响。我们还研究了硫酸鱼精蛋白(PS)、诺其、活化凝血酶原复合物(FEIBA)和新鲜冰冻血浆(FFP)逆转不同类肝素诱导的最大抗凝作用的能力。CAT是唯一能检测所有抗凝剂引起的凝血病的检测方法。PS能完全逆转UFH的抗凝作用,且这一过程可用所有三种检测方法进行监测。替扎肝素在体外也可用高剂量PS完全中和,但PS对依诺肝素的最大逆转率仅约为60%。磺达肝癸钠对APTT无显著影响,PS对其逆转也无显著作用。只有诺其能够纠正磺达肝癸钠诱导的CAT异常,同时对抗Xa水平无影响。在达那肝素加样血浆中,没有一种逆转剂非常有效,但高剂量的诺其使内源性凝血酶原时间(ETP)增加了40%,并使抗Xa水平从0.93降至0.78 IU/ml。我们得出结论,CAT优于传统凝血检测方法,因为它不仅能检测所有类肝素引起的凝血病,还可用于监测它们的逆转情况。

相似文献

1
Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.凝血酶生成试验在体外评估抗凝逆转方面优于传统检测方法。
Thromb Haemost. 2008 Aug;100(2):350-5.
2
Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa.基于检测的阿加曲班对未分级肝素、依诺肝素和磺达肝癸钠的中和作用谱的差异。
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029619895120. doi: 10.1177/1076029619895120.
3
Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.普通肝素、低分子量肝素和类肝素对凝血血栓弹力图测定的影响。
Am J Clin Pathol. 2000 May;113(5):725-31. doi: 10.1309/Q4AE-BMCW-CQ7J-NUVT.
4
The in vitro anticoagulant effects of danaparoid, fondaparinux, and lepirudin in children compared to adults.
Thromb Res. 2008;122(5):709-14. doi: 10.1016/j.thromres.2008.02.001. Epub 2008 Apr 1.
5
Direct thrombin inhibitors and factor xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant.直接凝血酶抑制剂和因子 Xa 抑制剂可影响稀释的凝血酶原时间,该时间可作为狼疮抗凝物的初始筛查。
Arch Pathol Lab Med. 2013 Jul;137(7):967-73. doi: 10.5858/arpa.2012-0236-OA.
6
In vitro and in vivo characterization of a reversible synthetic heparin analog.一种可逆合成肝素类似物的体外和体内特性研究
Thromb Res. 2016 Feb;138:121-129. doi: 10.1016/j.thromres.2015.12.007. Epub 2015 Dec 10.
7
Novel design of peptides to reverse the anticoagulant activities of heparin and other glycosaminoglycans.用于逆转肝素和其他糖胺聚糖抗凝活性的新型肽设计。
Thromb Haemost. 2001 Mar;85(3):482-7.
8
Reversing anticoagulants both old and new.逆转新旧抗凝剂。
Can J Anaesth. 2002 Jun-Jul;49(6):S11-25.
9
Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC.利伐沙班对重组活化凝血因子VII、活化凝血酶原复合物和凝血酶原复合物所致凝血酶生成抑制作用的逆转。
Thromb Res. 2009 Mar;123(5):796-8. doi: 10.1016/j.thromres.2008.07.007. Epub 2008 Sep 3.
10
Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo.新型串联肝素结合肽在体外患者血浆及体内大鼠中可逆转肝素和低分子量肝素的抗凝活性。
Blood. 2004 Feb 15;103(4):1356-63. doi: 10.1182/blood-2003-07-2334. Epub 2003 Oct 23.

引用本文的文献

1
"In Less than No Time": Feasibility of Rotational Thromboelastometry to Detect Anticoagulant Drugs Activity and to Guide Reversal Therapy.“转眼间”:旋转血栓弹力图检测抗凝药物活性及指导逆转治疗的可行性
J Clin Med. 2022 Mar 4;11(5):1407. doi: 10.3390/jcm11051407.
2
Calibrated Automated Thrombinography (CAT), a Tool to Identify Patients at Risk of Bleeding during Anticoagulant Therapy: A Systematic Review.校准自动凝血酶生成检测(CAT):一种识别抗凝治疗期间出血风险患者的工具——系统评价
TH Open. 2018 Sep 26;2(3):e291-e302. doi: 10.1055/s-0038-1672183. eCollection 2018 Jul.
3
The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency.
用于评估达比加群酯疗效的凝血酶生成试验的改良。
Sci Rep. 2016 Jul 5;6:29242. doi: 10.1038/srep29242.
4
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.颅内出血中抗栓药物逆转指南:神经重症监护学会和危重症医学会给医疗保健专业人员的声明
Neurocrit Care. 2016 Feb;24(1):6-46. doi: 10.1007/s12028-015-0222-x.
5
Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.新型口服抗凝药的逆转策略:发展现状、可能的临床应用及未来展望
Drug Saf. 2016 Jan;39(1):5-13. doi: 10.1007/s40264-015-0357-x.
6
Plasma from chronic liver disease subjects exhibit differential ability to generate thrombin.慢性肝病患者的血浆产生凝血酶的能力存在差异。
Blood Coagul Fibrinolysis. 2015 Oct;26(7):844-7. doi: 10.1097/MBC.0000000000000365.
7
The new oral anticoagulants and the future of haemostasis laboratory testing.新型口服抗凝药物与止血实验室检测的未来。
Biochem Med (Zagreb). 2012;22(3):329-41. doi: 10.11613/bm.2012.035.
8
Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and -B.抗 A 和抗 B 体外暴露后血小板功能和凝血形成动力学的改变。
Transfusion. 2013 Feb;53(2):382-93. doi: 10.1111/j.1537-2995.2012.03718.x. Epub 2012 May 25.
9
Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.肠外抗凝剂:抗血栓治疗与血栓预防,第 9 版:美国胸科医师学会循证临床实践指南。
Chest. 2012 Feb;141(2 Suppl):e24S-e43S. doi: 10.1378/chest.11-2291.
10
Decline in platelet microparticles contributes to reduced hemostatic potential of stored plasma.血小板微粒的减少导致储存血浆的止血潜能降低。
Thromb Res. 2011 Jul;128(1):35-41. doi: 10.1016/j.thromres.2011.02.011. Epub 2011 Mar 21.